Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Crystallographic Analysis Reveals that Anticancer Clinical Candidate L-778,123 Inhibits Protein Farnesyltransferase and Geranylgeranyltransferase-I by Different Binding Modes

Reid, T. Scott, Long, Stephen B., Beese, Lorena S. · 2004 · Biochemistry

Abstract

Many signal transduction proteins that control growth, differentiation, and transformation, including Ras GTPase family members, require the covalent attachment of a lipid group by protein farnesyltransferase (FTase) or protein geranylgeranyltransferase type-I (GGTase-I) for proper function and for the transforming activity of oncogenic mutants. FTase inhibitors are a new class of potential cancer therapeutics under evaluation in human clinical trials. Here, we present crystal structures of the clinical candidate L-778,123 complexed with mammalian FTase and complexed with the related GGTase-I enzyme. Although FTase and GGTase-I have very similar active sites, L-778,123 adopts different binding modes in the two enzymes; in FTase, L-778,123 is competitive with the protein substrate, whereas in GGTase-I, L-778,123 is competitive with the lipid substrate and inhibitor binding is synergized by tetrahedral anions. A comparison of these complexes reveals that small differences in protein structure can dramatically affect inhibitor binding and selectivity. These structures should facilitate the design of more specific inhibitors toward FTase or GGTase-I. Finally, the binding of a drug and anion together could be applicable for developing new classes of inhibitors.

Overview

Integrity signals

Registry

Crossref · 10.1021/bi049280b

Cites

0 references resolved

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

None of the references could be matched to a known paper.

Research works printed but not linked: 53

  1. Tamanoi F., 2001, The Enzymes, 322
  2. Haluska P., Eur. J. Cancer, 38, 1700
  3. Caponigro F., 2003, Expert Opin. Invest. Drugs 12, 943−954.
  4. Cortes J. E., 2002, ZARNESTRATM (R115777), in chronic myeloid leukemia and other other hematological malignancies, Blood 31, 31.
  5. Fu H. W., 1999, Recent Prog. Horm. Res. 54, 315−342.
  6. Barbacid M., 1987, Annu. Rev. Biochem. 56, 779−827.
  7. Kato K., 1992, Proc. Natl. Acad. Sci. U.S.A. 89
  8. Cox A. D., 2001, Drugs 61, 723−732.
  9. Long S. B., 1998, Biochemistry 37, 9612−9618.
  10. Long S. B., 2000, Structure 8, 209−222.
  11. Strickland C. L., 1998, Biochemistry 37, 16601−16611.
  12. Park H.-W., 1800, Science, 275, 1804
  13. Long S. B., 2002, Nature 419, 645−650.
  14. Taylor J. S., EMBO J., 22, 5974
  15. Long S. B., 2001, Proc. Natl. Acad. Sci. U.S.A. 98
  16. Bell I. M., J. Med. Chem., 45, 2409
  17. deSolms S. J., J. Med. Chem., 46, 2984
  18. Strickland C. L., J. Med. Chem., 42, 2135
  19. Reiss Y., 1990, Inhibition of purified
  20. Dinsmore C. J., 2003, Chem. 3, 1075−1093.
  21. Sebti S. M., 2000, Oncogene 19, 6584−6593.
  22. Dinsmore C. J., J. Am. Chem. Soc., 123, 2108
  23. Huber H. E., J. Biol. Chem., 276, 24465
  24. Zhang F. L., J. Biol. Chem., 269, 23470
  25. Otwinowski Z., 1997, Methods Enzymol. 276A, 307−326.
  26. Brünger A. T., 1998, Acta Crystallogr., Sect. D 54, 905−921.
  27. Jones T. A., 1993, The manual
  28. Word J. M., J. Mol. Biol., 285, 1733
  29. Guex N., 1997, Electrophoresis 18, 2714−2723.
  30. De Moliner E., Eur. J. Biochem., 270, 3181
  31. Vogt A., 1991, Oncogene, 13, 1999
  32. Stark W. W., Jr., Am. J. Physiol., 275, L63
  33. Sun J., 2003, Cancer Res. 63, 8922−8929.
  34. Walters C. E., J. Immunol., 168, 4094
  35. Lobell R. B., 2001, Cancer Res. 61, 8758−8768.
  36. Wong W. W., 2002, Leukemia 16, 508−519.
  37. Reid T. S., 2004, Biochemistry 43, 6877−6884.
  38. Del Villar K., J. Biol. Chem., 274, 27017
  39. Buckner F. S., 2002, Mol. Biochem. Parasitol. 122, 181−188.
  40. Murthi K. K., 1935, Bioorg. Med. Chem. Lett., 13, 1937
  41. Chakrabarti D., 1998, Mol. Biochem. Parasitol. 94, 175−184.
  42. Segel, I. H. (1975)Enzyme Kinetics: Behaviour and Analysis of Rapid Equilibrium and Steady-State Systems, pp 465−504, Wiley, New York.
  43. Theorell H., 1965, Arch. Biochem. Biophys. 110, 413−421.
  44. Pylypenko O., 2003, Mol. Cell 11, 483−494.
  45. Zhang H., 2000, Structure 8, 241−251.
  46. Scholten J. D., J. Biol. Chem., 272, 18081
  47. Hajduk P. J., J. Med. Chem., 43, 4786
  48. Szczepankiewicz B. G., J. Am. Chem. Soc., 125, 4096
  49. Erlanson D. A., 2000, Proc. Natl. Acad. Sci. U.S.A. 97
  50. Seidel H. M., 1994, Biochemistry 33, 5641−5646.
  51. Zhou G., 1998, Proc. Natl. Acad. Sci. U.S.A. 95
  52. Milner-White E. J., Biochem. J., 122, 740
  53. Abbreviations FPP, farnesyl diphosphate

Cited by

See all 54

Metadata

Authors
Reid, T. S., Long, S. B., & Beese, L. S.
Affiliations
Duke Medical Center (US)
Venue
Biochemistry
Published
2004-06-23
Volume
43
Issue
28
Pages
9000-9008
ISSN
  • 0006-2960 (ISSN-L)
  • 1520-4995
OpenAlex
W2016552910
Cited by
51
References
1
Citations by year
2026: 2 · 2023: 2 · 2022: 3 · 2020: 5 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 3 · 2013: 3 · 2012: 2
FWCI
1.30
Type
journal article
Language
en
Open access
closed
Locations
  • Biochemistry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute of General Medical Sciences (GM52382)
  • National Center for Research Resources (RR07 707)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
farnesyltransferase, geranylgeranyltransferase I, Ras GTPase, lipid modification, competitive inhibition, tetrahedral anions, enzyme selectivity, crystal structure, anticancer drug design
MeSH terms
Animals, Antineoplastic Agents, Binding, Competitive, Enzyme Inhibitors, Humans, Imidazoles, Models, Molecular, Protein Binding, Protein Conformation, Structure-Activity Relationship, Crystallography, X-Ray, Alkyl and Aryl Transferases, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Crystallographic Analysis Reveals that Anticancer Clinical Candidate L-778,123 Inhibits Protein Farnesyltransferase and Geranylgeranyltransferase-I by Different Binding Modes. https://app.cochat.ai/papers/10.1021/bi049280b
The paper
Reid, T. S., Long, S. B., & Beese, L. S. (2004). Crystallographic Analysis Reveals that Anticancer Clinical Candidate L-778,123 Inhibits Protein Farnesyltransferase and Geranylgeranyltransferase-I by Different Binding Modes. Biochemistry. https://doi.org/10.1021/bi049280b

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.